UCUF-965
UCUF-965 is a CXCR4 positive allosteric modulator. UCUF-965 potentiates CXCL12-induced β-arrestin recruitment and cAMP signaling, activates lymphoblast migration, induces calcium flux, and does not bind CXCR4’s orthosteric CXCL12 site. UCUF-965 reduces miR-15b and miR-29a levels, increases miR-146a levels in fibroblasts. UCUF-965 enhances angiogenesis and reduces wound healing time in diabetic mice. UCUF-965 can be used for the research of diabetic wound healing impairment.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 2965316-77-0
- 分子式: C22H23N5OS
- 分子量:405.52
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
|
CXCR4 |
UCUF-965 (0.1-10 μM) promotes β-arrestin recruitment with an EC50 of 0.02 μM[1].
UCUF-965 acts as a partial agonist of CXCR4-mediated cAMP inhibition in CXCR4-overexpressing CHO cells, with an EC50 of 0.05 μM[1].
UCUF-965 (0.4 μM; 3 h) induces migration of CEM-CCRF human lymphoblast cells via CXCR4 activation, with an EC50 of 0.4 μM[1].
UCUF-965 (10 μM) induces CXCR4-mediated calcium flux in CEM-CCRF human lymphoblast cells[1].
UCUF-965 (0.1-10 μM; 24 h) modulates the expression of wound healing-related microRNAs in murine diabetic and non-diabetic fibroblasts, reducing miR-15b and miR-29a levels and increasing miR-146a levels[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:CEM-CCRF human lymphoblast cells
-
Concentration:0.4 μM
-
Incubation Time:3 h
-
Result:Induced CEM-CCRF cell migration with an EC50 of 0.4 μM and an average Eₘₐₓ of 31%.
-
Cell Line:murine diabetic (Db/Db) fibroblasts; murine non-diabetic (HZ) fibroblasts
-
Concentration:0.1, 1, 10 μM
-
Incubation Time:24 h
-
Result:Decreased the expression of miR-15b in both diabetic and non-diabetic fibroblasts in a dose-dependent manner.
Decreased miR-29a levels and increased miR-146a levels in both cell types, with responses observed at concentrations as low as 0.1 μM.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Db/Db mice (10-week-old female, diabetic model)[1]
-
Dosage:10 μM
-
Administration:intradermal injection; single dose (immediately after wounding)
-
Result:Reduced wound surface area compared to controls starting at post-injury day 6.
Achieved full wound closure at day 14, representing a 36% reduction in wound healing time compared to day 22 in PBS-treated controls.
Showed a significant increase in CD31-positive endothelial cells at day 7 post-wounding, reaching levels similar to non-diabetic control wounds.
化学情報
-
CAS 番号 2965316-77-0
-
分子量 405.52
-
分子式 C22H23N5OS
-
SMILES
N=1N=C(C=2C=CC=CC2OCC)N3N=C(C=4C=CC(=CC4)N5CCCC5)CSC13
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Powered by Bioz